CIDEC-related familial partial lipodystrophy

This symptom manifests as a noticeable reduction in fat tissue under the skin, particularly in the limbs and trunk. The biological mechanism involves mutations in the CIDEC gene, leading to impaired lipid storage in adipocytes. Over time, the loss of subcutaneous fat can lead to increased visibility of veins and muscular definition. This affects daily life by causing cosmetic concerns and potential psychological distress, which can be managed with counseling and cosmetic interventions.

Clinically, insulin resistance presents as elevated blood glucose levels despite normal or high insulin levels. It is caused by the inability of cells to respond effectively to insulin, often due to altered lipid metabolism. As it progresses, insulin resistance can lead to type 2 diabetes and associated complications. Management involves lifestyle modifications such as diet and exercise, and sometimes medication to improve insulin sensitivity.

Hypertriglyceridemia is characterized by elevated levels of triglycerides in the blood, which can be detected through blood tests. The condition arises due to impaired lipid metabolism and storage, leading to excess circulating lipids. Over time, it increases the risk of pancreatitis and cardiovascular disease. Patients may need dietary changes, medications, and regular monitoring to manage this condition effectively.

Acanthosis nigricans presents as dark, velvety patches of skin, often in body folds and creases. It is caused by insulin resistance, which stimulates keratinocyte and dermal fibroblast proliferation. The condition may become more pronounced over time if insulin resistance worsens. It can cause cosmetic concerns and discomfort, which can be alleviated with topical treatments and managing the underlying insulin resistance.

Hepatic steatosis, or fatty liver, is detected through imaging studies showing fat accumulation in the liver. It results from excessive lipid deposition due to metabolic dysregulation. If left unchecked, it can progress to non-alcoholic steatohepatitis (NASH) and liver fibrosis. Management includes lifestyle changes such as weight loss and dietary modifications to reduce liver fat content.

Hypertension is identified by persistently elevated blood pressure readings. It is often secondary to metabolic disturbances and increased cardiovascular risk associated with lipodystrophy. Over time, uncontrolled hypertension can lead to cardiovascular and renal complications. Management involves lifestyle interventions and antihypertensive medications to control blood pressure levels.

PCOS may manifest as irregular menstrual cycles, hirsutism, and polycystic ovaries on ultrasound. It is linked to insulin resistance and hyperinsulinemia, which disrupt normal ovarian function. Over time, PCOS can lead to infertility and metabolic complications. Treatment focuses on managing symptoms with hormonal therapies and addressing insulin resistance.

Muscle hypertrophy is observed as increased muscle mass and strength, often giving a muscular appearance. It occurs due to the redistribution of fat and compensatory muscle growth. While it may appear beneficial, it can mask underlying metabolic issues. Monitoring and managing metabolic health is crucial to prevent complications associated with lipodystrophy.

The clinician looks for abnormal fat distribution, particularly loss of subcutaneous fat in the limbs and trunk with possible fat accumulation in the face and neck. A detailed family history is crucial to identify hereditary patterns and any similar conditions in relatives. Physical examination may reveal acanthosis nigricans, hepatomegaly, and signs of insulin resistance. This step helps determine the likelihood of a lipodystrophy syndrome and guides further diagnostic testing.

Magnetic Resonance Imaging (MRI) is often used to assess fat distribution and confirm the loss of subcutaneous fat. Specific abnormalities include the absence of fat in the extremities and trunk with preservation or increase in visceral fat. These findings support the diagnosis of familial partial lipodystrophy and help exclude other conditions like generalized lipodystrophy. Imaging also assists in ruling out differential diagnoses such as Cushing's syndrome or anorexia nervosa.

Tests typically ordered include fasting glucose, insulin levels, lipid profile, and liver function tests. Biomarkers sought include elevated triglycerides, low HDL cholesterol, and evidence of insulin resistance or diabetes. Abnormal results often show hypertriglyceridemia, elevated liver enzymes, and hyperinsulinemia. These results guide the next steps in management, including lifestyle interventions and pharmacotherapy.

Genetic testing involves sequencing the CIDEC gene to identify pathogenic mutations. Common mutation types include missense, nonsense, or frameshift mutations that affect protein function. Positive results confirm the diagnosis of CIDEC-related familial partial lipodystrophy and provide a basis for genetic counseling. They also inform family members about their risk and guide decisions about genetic testing for relatives.